Literature DB >> 19223542

E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation.

Liliana Endo-Munoz1, Alison Dahler, Ngari Teakle, Danny Rickwood, Mehlika Hazar-Rethinam, Ibtissam Abdul-Jabbar, Scott Sommerville, Ian Dickinson, Pritinder Kaur, Sophie Paquet-Fifield, Nicholas Saunders.   

Abstract

The E2F family of transcription factors plays a crucial role in the regulation of genes involved in cell proliferation, differentiation, and apoptosis. In keratinocytes, the inhibition of E2F is a key step in the control and initiation of squamous differentiation. Because the product of the recently identified E2F7a/E2F7b gene has been shown to repress E2F-regulated promoters, and to be abundant in skin, we examined its role in the epidermis. Our results indicate that E2F7b mRNA expression is selectively associated with proliferation-competent keratinocytes. Moreover, E2F7 was able to antagonize E2F1-induced proliferation and apoptosis. In contrast, although E2F7 was able to inhibit proliferation and initiate differentiation, it was unable to antagonize the differentiation suppression induced by E2F1. These data indicate that E2F7-mediated suppression of proliferation and apoptosis acts through E2F1-dependent pathways, whereas E2F7-induced differentiation acts through an E2F1-independent pathway. These data also suggest that proliferation, differentiation, and survival of primary human keratinocytes can be controlled by the relative ratio of E2F1 to E2F7. Because deregulated proliferation, differentiation, and apoptosis are hallmarks of cancer, we examined the expression levels of E2F1 and E2F7 in cutaneous squamous cell carcinomas (CSCC). We found that both genes were overexpressed in CSCCs compared with normal epidermis. Furthermore, inhibition of E2F7 in a SCC cell line sensitized the cells to UV-induced apoptosis and doxorubicin-induced apoptosis. Combined, these data suggest that the selected disruption of E2F1 and E2F7 in keratinocytes is likely to contribute to CSCC formation and may prove to be a viable therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223542     DOI: 10.1158/0008-5472.CAN-08-2725

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression.

Authors:  Luis A Carvajal; Pierre-Jacques Hamard; Crystal Tonnessen; James J Manfredi
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

2.  Involvement of atypical transcription factor E2F8 in the polyploidization during mouse and human decidualization.

Authors:  Qian-Rong Qi; Xu-Yu Zhao; Ru-Juan Zuo; Tong-Song Wang; Xiao-Wei Gu; Ji-Long Liu; Zeng-Ming Yang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  E2F8 as a Novel Therapeutic Target for Lung Cancer.

Authors:  Sin-Aye Park; James Platt; Jong Woo Lee; Francesc López-Giráldez; Roy S Herbst; Ja Seok Koo
Journal:  J Natl Cancer Inst       Date:  2015-06-18       Impact factor: 13.506

Review 4.  Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Authors:  Hui-Zi Chen; Shih-Yin Tsai; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

5.  PIR promotes tumorigenesis of breast cancer by upregulating cell cycle activator E2F1.

Authors:  Muhammad Suleman; Ai Chen; Huanhuan Ma; Shixiong Wen; Wentao Zhao; Donghai Lin; Guode Wu; Qinxi Li
Journal:  Cell Cycle       Date:  2019-09-10       Impact factor: 4.534

6.  Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.

Authors:  Sarina Cameron; Lilia Merida de Long; Mehlika Hazar-Rethinam; Eleni Topkas; Liliana Endo-Munoz; Andrew Cumming; Orla Gannon; Alexander Guminski; Nicholas Saunders
Journal:  Mol Cancer       Date:  2012-09-28       Impact factor: 27.401

7.  Pseudomonas aeruginosa exotoxin A reduces chemoresistance of oral squamous carcinoma cell via inhibition of heat shock proteins 70 (HSP70).

Authors:  Sang Rye Park; Kyoung Duk Lee; Uk Kyu Kim; Young Gi Gil; Kyu Seon Oh; Bong Soo Park; Gyoo Cheon Kim
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 3.052

8.  Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.

Authors:  R B Erlich; Z Kherrouche; D Rickwood; L Endo-Munoz; S Cameron; A Dahler; M Hazar-Rethinam; L M de Long; K Wooley; A Guminski; N A Saunders
Journal:  Br J Cancer       Date:  2011-11-24       Impact factor: 7.640

9.  Potential role of a navigator gene NAV3 in colorectal cancer.

Authors:  E Carlsson; A Ranki; L Sipilä; L Karenko; W M Abdel-Rahman; K Ovaska; L Siggberg; U Aapola; R Ässämäki; V Häyry; K Niiranen; M Helle; S Knuutila; S Hautaniemi; P Peltomäki; K Krohn
Journal:  Br J Cancer       Date:  2011-12-15       Impact factor: 7.640

10.  Identifying an lncRNA-Related ceRNA Network to Reveal Novel Targets for a Cutaneous Squamous Cell Carcinoma.

Authors:  Yaqin Xu; Yingying Dong; Yunhua Deng; Qianrong Qi; Mi Wu; Hongmei Liang; Qiuyun She; Qing Guo
Journal:  Biology (Basel)       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.